Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes

Cited by (203)

Items 101–200 of 203

1. Sodium‐glucose cotransporter 2 inhibition does not reduce hepatic steatosis in overweight, insulin‐resistant patients without type 2 diabetes
   Thomas Marjot, Charlotte Green, Catriona A. Charlton, Thomas Cornfield, Jonathan Hazlehurst, Ahmad Moolla, Sarah J. White, Jane M Francis, Stefan Neubauer, Jeremy Cobbold et al. · 2019 · JGH Open
2. Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)
   Associazione Italiana per lo Studio del Fegato (AISF), Società Italiana di Diabetologia (SID) and Società Italiana dell’Obesità (SIO) · 2021 · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity
3. Therapies for non-alcoholic fatty liver disease: A 2022 update
   Katie Shen, Achintya Dinesh Singh, Jamak Modaresi Esfeh, Jamilé Wakim-Fleming · 2022 · World Journal of Hepatology
4. Metabolic dysfunction associated steatotic liver disease: Current practice, screening guidelines and management in the primary care setting
   Udita Gupta, Thomas M. Ruli, Danyaal Buttar, Mohamed Shoreibah, Meagan E. Gray · 2023 · The American Journal of the Medical Sciences
5. Canagliflozin ameliorates hepatic fat deposition in obese diabetic mice: Role of prostaglandin E2
   Kei Yoshino, Tetsuya Hosooka, Masakazu Shinohara, Chikako Aoki, Yusei Hosokawa, Makoto Imamori, Wataru Ogawa · 2021 · Biochemical and Biophysical Research Communications
6. Therapeutics for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
   Kamlesh K. Bhopale, Mukund P. Srinivasan · 2023 · Livers
7. Validation of a diet‐induced Macaca fascicularis model of non‐alcoholic steatohepatitis with dietary and pioglitazone interventions
   Raul C. Camacho, David Polidori, Tao Chen, Bin Chen, Helen Han Hsu, Bin Gao, Mathieu Marella, Mariusz S. Lubomirski, Traymon Beavers, Javier Cabrera et al. · 2022 · Diabetes Obesity and Metabolism
8. Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Causation or Association
   Atul Deep Bali, Akiva Rosenzveig, William H. Frishman, Wilbert S. Aronow · 2023 · Cardiology in Review
9. Therapeutic Potentials of Reducing Liver Fat in Non-Alcoholic Fatty Liver Disease: Close Association with Type 2 Diabetes
   Georgios Tsamos, Dimitra Vasdeki, Theocharis Koufakis, Vasiliki Michou, Kali Makedou, Georgios Tzimagiorgis · 2023 · Metabolites
10. Role of anti-diabetic medications in the management of MASLD
    Scott D. Isaacs, Fiona V Farrelly, Paul Brennan · 2025 · Frontline Gastroenterology
11. Nonalcoholic fatty liver disease should be considered for treatment allocation in standard management algorithms for type 2 diabetes
    Mohammad Shafi Kuchay, Narendra Singh Choudhary, Sunil Kumar Mishra, Anoop Misra · 2020 · Diabetes & Metabolic Syndrome Clinical Research & Reviews
12. Approach to the Patient With Nonalcoholic Fatty Liver Disease
    Renata Belfort‐DeAguiar, Romina Lomonaco, Kenneth J. Cusi · 2022 · The Journal of Clinical Endocrinology & Metabolism
13. Nonalcoholic fatty liver disease
    Evangelia S. Makri, Stergios A. Pοlyzos · 2022 · Journal of Atherosclerosis Prevention and Treatment
14. Therapeutic developments in metabolic dysfunction-associated fatty liver disease
    Yiwen Shi, Jian‐Gao Fan · 2022 · Chinese Medical Journal
15. Comparative efficacy of glucose-lowering drugs on liver steatosis as assessed by means of magnetic resonance imaging in patients with type 2 diabetes mellitus: systematic review and network meta-analysis
    Konstantinos Malandris, Stylianos Papandreou, Ioannis Avgerinos, Thomas Karagiannis, Paschalis Paschos, Theodoros Michailidis, Aris Liakos, Eleni Bekiari, Emmanouil Sinakos, Απόστολος Τσάπας · 2023 · HORMONES
16. Global Prevalence, Incidence, and Outcomes of Coexisting MASLD and Chronic Kidney Disease: A Meta‐Analysis
    Martin Tze Wah Kueh, J Q Yeo, Yiming Chen, Nicole Ying Zi Chua, Hui Lian Koh, Seng Pei Khaw, Hassan Jabbar, Jiong‐Wei Wang, Kwan Seung S Lee, Yip Han Chin et al. · 2026 · Liver International
17. The sodium–glucose cotransporter 2 inhibitor ipragliflozin improves liver function and insulin resistance in Japanese patients with type 2 diabetes
    Tsuyoshi Okura, Yohei Fujioka, Risa Nakamura, Sonoko Kitao, Yuichi Ito, Mari Anno, Kazuhisa Matsumoto, Kyoko Shoji, K. Matsuzawa, Shoichiro Izawa et al. · 2022 · Scientific Reports
18. Role of diabetologists in the management of nonalcoholic fatty liver disease: Primary prevention and screening/management of fibrosis and cirrhosis
    Mohammad Shafi Kuchay, Anoop Misra · 2022 · Diabetes & Metabolic Syndrome Clinical Research & Reviews
19. The Emerging Therapeutic Promise of SGLT2 Inhibitors in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Wenjing Zhang, Huaidong Hu · 2025 · Digestive Diseases and Sciences
20. Why do some glucose‐lowering agents improve non‐alcoholic fatty liver disease whereas others do not? A narrative review in search of a unifying hypothesis
    Gea Ciccarelli, Gianfranco Di Giuseppe, Francesca Cinti, Simona Moffa, Teresa Mezza, Andrea Giaccari · 2023 · Diabetes/Metabolism Research and Reviews
21. Effects of the SGLT2 inhibitor ipragliflozin and metformin on hepatic steatosis and liver fibrosis: Sub‐analysis of a randomized controlled study
    Kiichi Hirayama, Masaya Koshizaka, Ryoichi Ishibashi, Mayumi Shoji, Takuro Horikoshi, Kenichi Sakurai, Koutaro Yokote, PRIME‐V Study Group · 2025 · Diabetes Obesity and Metabolism
22. Metabolic-Associated Steatotic Liver Disease (MASLD) and Type 2 Diabetes: Mechanisms, Diagnostic Approaches, and Therapeutic Interventions
    Anastasia Ntikoudi, Anastasia Papachristou, Afroditi Tsalkitzi, Nikoletta Margari, Eleni Evangelou, Eugenia D. Vlachou · 2025 · Diabetology
23. Age, sex, disease severity, and disease duration difference in placebo response: implications from a meta-analysis of diabetes mellitus
    Chu Lin, Xiaoling Cai, Wenjia Yang, Fang Lv, Lin Nie, Linong Ji · 2020 · BMC Medicine
24. Nonalcoholic Fatty Liver Disease (NAFLD) for Primary Care Providers: Beyond the Liver
    Eddison Godinez Leiva, Fernando Bril · 2020 · Current Hypertension Reviews
25. Diagnosis and Management of MASLD: An Metabolic Perspective of a Multisystem Disease
    Vanishri Ganakumar, Tejaswi Halebidu, Manjunath Goroshi, Vikrant Ghatnatti · 2024 · International journal of clinical metabolism and diabetes.
26. New advances in drug development for metabolic dysfunction-associated diseases and alcohol-associated liver disease
    Jinming Zhang, Yixin Li, Yang Liu, Ningning Ma, Shengying Qian, Yingfen Chen, Yajun Duan, Xiaogang Xiang, Yong He · 2024 · Cell & Bioscience
27. Biomarkers for Assessing Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus on Sodium–Glucose Cotransporter 2 Inhibitor Therapy
    Farah Khaznadar, Ana Petrovic, Omar Khaznadar, Hrvoje Roguljić, Kristina Bojanić, Lucija Kuna, Stjepan Siber, Robert Smolić, Ines Bilić-Čurčić, George Y. Wu et al. · 2023 · Journal of Clinical Medicine
28. Review article: the impact of liver‐directed therapies on the atherogenic risk profile in non‐alcoholic steatohepatitis
    Margery A. Connelly, Jonathan Velez Rivera, John R. Guyton, Mohammad Shadab Siddiqui, Arun Jayant Sanyal · 2020 · Alimentary Pharmacology & Therapeutics
29. Target Therapies for NASH/NAFLD: From the Molecular Aspect to the Pharmacological and Surgical Alternatives
    Michele Finotti, Maurizio Romano, Pasquale Auricchio, Michele Scopelliti, Marco Brizzolari, Ugo Grossi, Marco Piccino, Stefano Benvenuti, Giovanni Morana, Umberto Cillo et al. · 2021 · Journal of Personalized Medicine
30. Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Hepatic Fibrosis in Patients With Type 2 Diabetes: A Chart-Based Analysis
    Hisayuki Katsuyama, Mariko Hakoshima, Takehiro Iijima, Hiroki Adachi, Hidekatsu Yanai · 2020 · Journal of Endocrinology and Metabolism
31. Management of patients with type 2 diabetes and MASLD: An overview and joint statement
    Yasmina Chouik, Clémence M. Canivet, Jean‐Baptiste Julla, Thomas Mouillot, Lucia Parlati, Alexia Rouland, Sarra Smati, Blandine Tramunt, Rodolphe Anty, Jérôme Boursier et al. · 2025 · Diabetes & Metabolism
32. Meta-analysis of trials in non-alcoholic fatty liver disease with therapeutic interventions for metabolic syndrome
    Stewart Gary Albert, Emily M. Wood · 2021 · Diabetes & Metabolic Syndrome Clinical Research & Reviews
33. State-of-the-Art Overview of the Pharmacological Treatment of Non-Alcoholic Steatohepatitis
    Yongin Cho, Yong‐ho Lee · 2022 · Endocrinology and Metabolism
34. Guía de práctica clínica multidisciplinar de manejo de la esteatosis hepática metabólica
    Manuel Romero‐Gómez, Javier Escalada, Mar Noguerol, Antonio Pérez, Juana Carretero, Javier Crespo, Juan J Mascort, Ignacio Aguilar, Francisco José Tinahones, Pedro Cañones et al. · 2025 · Gastroenterología y Hepatología
35. Close multilevel links between metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus
    Adriaan Georgius Holleboom, Sven Francque, Kenneth J. Cusi, Cyrielle Caussy · 2025 · Metabolism Open
36. Current Treatment Options, Including Diet, Exercise, and Medications
    Mazen Noureddin, Manal F. Abdelmalek · 2023 · Clinics in Liver Disease
37. Inflammation in Steatotic Liver Diseases: Pathogenesis and Therapeutic Targets
    Shengying Qian, Xiaolin Wang, Yingfen Chen, Qiuhong Zai, Yong He · 2024 · Seminars in Liver Disease
38. Evolution of characteristics of MASLD with and without diabetes: a meta-analysis of placebo arms
    Han Ah Lee, Hye Ah Lee, Hwi Young Kim · 2024 · Scientific Reports
39. Diverting hepatic lipid fluxes with lifestyles revision and pharmacological interventions as a strategy to tackle steatotic liver disease (SLD) and hepatocellular carcinoma (HCC)
    Davide Misceo, Gabriele Mocciaro, Simona D’Amore, Michèle Vacca · 2024 · Nutrition & Metabolism
40. Targeting Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Available and Future Pharmaceutical Options
    Emmanouil Koullias, Maria Papavdi, John S. Koskinas, Melanie J. Deutsch, Anastasia C. Thanopoulou · 2025 · Cureus
41. Metabolic dysfunction-associated steatotic liver disease - A new indication for sodium-glucose Co-transporter-2 inhibitors
    Grzegorz Procyk, Jakub Jaworski, Aleksandra Gąsecka, Krzysztof Jerzy Filipiak, Josip A. Borovac · 2024 · Advances in Medical Sciences
42. Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus
    Eliza Mankieva, Кухарева Елена Ивановна · 2023 · Russian Journal of Evidence-Based Gastroenterology
43. Effect of newer antihyperglycemic drugs on liver steatosis indices in patients with diabetes and obesity
    Juana Carretero‐Gómez, Javier Ena, José Miguel Seguí Ripoll, Francisco Javier Carrasco-Sánchez, Ricardo Gómez‐Huelgas, José Manuel Casas Rojo, Manuel Suárez Tembra, Juan Jesús Carabantes Rueda, José Carlos Arévalo‐Lorido · 2021 · Current Medical Research and Opinion
44. The Emerging Role of Anti-Hyperglycemic Agents for the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease
    Silvia Pieralice, Rocco Amendolara, Valentina Berna, Giuseppina Manganaro, Annalisa Zurru, Luca D’Onofrio, Renata Risi, Marianna Alfonsi, Ernesto Maddaloni, Raffaella Buzzetti · 2025 · Diabetes Metabolic Syndrome and Obesity
45. Dapagliflozin‐Associated Reduction in Liver Fat Is Independent of Weight Loss in Patients With Type 2 Diabetes
    Anna V. Naumova, Guilherme Moura Cunha, Nicole J. Kim, Jie Lu, Daniel A. Isquith, Baocheng Chu, Charles C. Maynard, Arash Mahdavi, Negar Firoozeh, Karen Gomes Ordovas et al. · 2026 · Obesity
46. Emerging Therapies and Therapeutic Targets for Composite Liver Disease: NASH
    Masilamani Elizabeth Sobhia, Sonia Kumari, Harish Kumar, Akshata Gandhe, Dhriti Kaushik, Harish Kumar, Jethender Jain, Ankita Ankita, Moyim Mallick, Bommana Pavani et al. · 2023 · Current Topics in Medicinal Chemistry
47. Unraveling the mechanisms of hepatogenous diabetes and its therapeutic perspectives
    Manisha C. Yadav, Smriti Verma, Purnima Tiwari, Madhav Nilakanth Mugale · 2024 · Life Sciences
48. Personalized approach for type 2 diabetes pharmacotherapy: where are we and where do we need to be?
    Muhammad A Abdul‐Ghani, Ralph Anthony DeFronzo · 2021 · Expert Opinion on Pharmacotherapy
49. Association between serum insulin levels and heart failure-related parameters in patients with type 2 diabetes and heart failure treated with canagliflozin: a post-hoc analysis of the randomized CANDLE trial
    Atsushi Tanaka, Takumi Imai, Michio Shimabukuro, Isao Taguchi, Akira Sezai, Shigeru Toyoda, Hirotaka Watada, Junya Ako, Koichi Node, the CANDLE trial investigators · 2022 · Cardiovascular Diabetology
50. Insulin clearance and incretin hormones following oral and “isoglycemic” intravenous glucose in type 2 diabetes patients under different antidiabetic treatments
    Andrea Tura, Christian S. Göbl, Irfan Vardarli, Giovanni Pacini, Michael Albrecht Nauck · 2022 · Scientific Reports
51. Newer and novel antidiabetic drug classes across the cardiovascular–kidney–metabolic continuum
    Konstantinos Stefanakis, Paschalis Karakasis, Dimitra Vasdeki, Djordje S. Popovic, Dimitrios Patoulias, Manfredi Rizzo, Christos Socrates Mantzoros · 2026 · Endocrine Reviews
52. Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 2)
    Авагимян Ашот Арманович, Mohammad Sheibani, А. И. Трофименко, Evgenii E. Lysov, Farida Muinovna Khamidova, Anahit Aznauryan, Lilit M. Sukiasyan, Karmen Sahakyan, Tamara R. Gevorgyan, Marina R. Tatoyan et al. · 2025 · Innovative medicine of Kuban
53. Current and Emerging Treatments for Metabolic Associated Steatotic Liver Disease and Diabetes: A Narrative Review
    Rachelle Choi, Jatin P. Vemuri, Alekya Poloju, Rishi Raj, Anurag Mehta, Amon Asgharpour, Mohammad Shadab Siddiqui, Priyanka Majety · 2025 · Endocrines
54. A nem alkoholos zsírmájbetegség és a 2-es típusú cukorbetegség.
    Alajos Pár, István Wittmann, Gabriella Pár · 2022 · Orvosi Hetilap
55. Potential new application points of SGLT2 inhibitors in patients with heart failure in combination with diabetes mellitus, non-alcoholic fatty liver disease and anemia (literature review)
    Цыганкова Оксана Васильевна, О. В. Тимощенко, O. V. Tuzovskaia, Lydmila D. Latyntseva, К. Yu. Nikolaev · 2022 · Сибирский научный медицинский журнал
56. Prospects of using sodium-glucose co-transporter-2 (SGLT-2) inhibitors in patients with metabolic-associated fatty liver disease (MAFLD)
    Iryna Oleksandrivna Kostitska, Nadia Protas, Liliia Petrovska · 2023 · Diabetes Obesity Metabolic Syndrome
57. Pharmacological Treatment of Diabetes Mellitus: An Overview of New Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Diabetes Mellitus
    Mateusz Nieczyporuk, Paweł Tyrna, Tomasz Cader, Aleksandra Sikora, Szymon Staneta · 2024 · Journal of Endocrinology and Metabolism
58. Effect of bariatric endoscopy on liver fibrosis and steatosis and the course of NAFLD – a prospective interventional study
    Adam Vašura, Evžen Machytka, Ondřej Urban, Jitka Macháčková, Lubomír Pavliska, Zdeněk Berka, Zdeněk Švagera, Marek Bužga · 2024 · Annals of Hepatology
59. Type 2 diabetes mellitus, non-alcoholic fatty liver disease and cardiovascular disease: causal relationships and the role of anti-diabetic drugs
    Tatiana Yu. Demidova, Д. В. Скуридина, E. S. Pervushina · 2023 · FOCUS Endocrinology
60. Clinical management of MASLD and MASH—An overview
    Paul Horn, Philip Noel Newsome · 2024 · Elsevier eBooks
61. Canagliflozin: from glycemic control to improvement of cardiovascular and renal prognosis in patients with type 2 diabetes mellitus. Resolution of Advisory Board
    Marina Vladimirovna Shestakova, Ametov As, M. B. Antsiferov, Tatiana Prokop'evna Bardymova, Farida Vadutovna Valeeva, Gagik Radikovich Galstyan, Tatiana Yu. Demidova, Irina Al'bertovna Karpova, Т. П. Киселева, Alexander Yur'evich Mayorov et al. · 2022 · Diabetes Mellitus
62. Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD
    Takahashi, Hirokazu, Kessoku, Takaomi, Kawanaka, Miwa, Nonaka, Michihiro, Hyogo, Hideyuki, Fujii, Hideki, Nakajima, Tomoaki, Imajo, Kento, Tanaka, Kenichi, Kubotsu, Yoshihito et al. · 2025 · Diabetes mellitus
63. Multidisciplinary clinical practice guideline on the management of metabolic hepatic steatosis
    Manuel Romero‐Gómez, Javier Escalada, Mar Noguerol, Antonio Pérez, Juana Carretero, Javier Crespo, Juan José Mascort, Ignacio Aguilar, Francisco José Tinahones, Pedro Cañones et al. · 2025 · Gastroenterología y Hepatología (English Edition)
64. Comparative risk of fibrosis progression with sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitors in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus with low-to-intermediate fibrosis
    Jonggi Choi, Daniel Fulop, Vy H. Nguyen, Eric M. Przybyszewski, Jiunn Song, Allison Carroll, Megan Michta, Erik Almazan, Tracey G. Simon, Raymond T. Chung · 2025 · Clinical and Molecular Hepatology
65. Metabolic Liver Disease Beyond the Liver
    Amalia Gastaldelli, Frank Tacke, Adriaan Georgius Holleboom · 2026 · Clinics in Liver Disease
66. Lean metabolic dysfunction-associated steatotic liver disease: Current insights and knowledge gaps
    Praveen Sandeep Raj R., Rebecca John, Felix Manoharan, Asisha M. Janeela, Ashish Goel, Nitin Kapoor · 2026 · Best Practice & Research Clinical Endocrinology & Metabolism
67. Effects of canagliflozin are mostly observed at first follow-up, within 6 months of commencement: results for the ABCD canagliflozin audit
    Thomas Simon James Crabtree, Peter H. Winocour, Ken H. Darzy, Suzanne M. Phillips, Alison J Evans, Anurita Rohilla, Rajeev Raghavan, DEVESH K. SENNIK, Alex S. T. Bickerton, ISKANDAR RAUF IDRIS et al. · 2020 · British Journal of Diabetes
68. NAFLD and type 2 diabetes: A practical guide for the joint management
    Idoia Genua, Paula Iruzubieta, Juan Carlos Rodríguez-Duque, Antonio Pérez, Javier Crespo · 2023 · Gastroenterología y Hepatología (English Edition)
69. Empagliflozin Treatment for Non-alcoholic Fatty Liver Disease in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Loiy Naser Alsarkhi, Sanjay Eda, Rahman Hameed Mohammed Abdul, Helai Hussaini, Olaniyi A Fadeyi, Sandipkumar S Chaudhari, Muhammad A. Rauf, Danish Allahwala · 2025 · Cureus
70. Hígado graso no alcohólico: certezas e incertidumbres de una epidemia silenciosa
    Esteban González Ballerga, Andrea Curia, Kenneth J. Cusi · 2020 · Acta gastroenteorológica latinoamericana/Acta gastroenterológica latinoamericana
71. Voies thérapeutiques dans l’hépatopathie stéatosique métabolique
    Sarra Smati, Clémence M. Canivet, Jérôme Boursier, Bertrand Cariou · 2023 · Médecine des Maladies Métaboliques
72. Corrigendum. Guía de práctica clínica multidisciplinar de manejo de la esteatosis hepática metabólica
    Manuel Romero-Gómez, Javier Escalada, Mar Noguerol, Antonio Pérez, Juana Carretero, Javier Crespo, Juan J Mascort, Ignacio Aguilar, Francisco Tinahones, Pedro Cañones et al. · 2026 · Gastroenterología y Hepatología
73. Empagliflozin senkt effektiv den Leberfettgehalt bei gut kontrolliertem Typ-2-Diabetes
    Rima Chakaroun · 2020 · Der Diabetologe
74. Nichtalkoholische Fettlebererkrankung und Typ‑2‑Diabetes
    Jennifer Pützer, SABINE KAHL · 2020 · Der Diabetologe
75. The Effect of Sodium-Glucose Cotransporter 2 Inhibitor Ipragliflozin on Insulin Resistance, Hepatic Insulin Clearance, Beta-Cell Function in the Japanese Patients with type 2 Diabetes
    Tsuyoshi Okura, Yohei Fujioka, Risa Nakamura, Sonoko Kitao, Yuichi Ito, Mari Anno, Kazuhisa Matsumoto, Kyoko Shoji, K. Matsuzawa, Shoichiro Izawa et al. · 2021 · Research Square
76. Gyrate Atrophy, High myopia, Night blindness, Ornithine Aminotransferase, Posterior sub capsular cataract.
    G Satyavathi, Y Srinivas, Malleswari · 2015
77. Non‐alcoholic liver disease (NAFLD)
    FRCP Rudy Bilous, Richard Donnelly, FRCP Iskandar Idris DM · 2021
78. Pharmacological Treatment of Nonalcoholic Fatty Liver Disease: Antidiabetic Agents
    Kyung‐Soo Kim · 2022 · Journal of Korean Diabetes
79. Obesity in relation to cardiorenal function
    Isabella Nguyen, Jaap A. Joles, Marianne Christina Verhaar, Hildo J. Lamb, Ilona A. Dekkers · 2023 · Elsevier eBooks
80. Hướng dẫn của Hiệp hội Nghiên cứu bệnh gan Châu Á Thái Bình Dương trong chẩn đoán và điều trị bệnh gan nhiễm mỡ liên quan chuyển hóa
    Tran Thi Khanh Tuong, Khoa Trần Hoàng Đăng · 2022 · Pham Ngoc Thach Journal of Medicine and Pharmacy
81. Effect of Canagliflozin on liver steatosis in obese non diabetic patients with non-alcoholicfatty liver disease: A double blind randomized controlled trial
    Borwonkhun Tontivuthikul, Witthawat Naeowong, Weerapan Khovidhunkit · 2019
82. Efeitos de diferentes protocolos de treinamento físico em vias biomoleculares de controle de produção hepática de glicose e metabolismo lipídico no fígado de roedores obesos
    Rodrigo Martins Pereira · 2021
83. Progress in the Study of the Hepatoprotective Effect of SGLT2i on NAFLD Patients with T2DM
    Fan Yang, Xiaoping Tan · 2024 · Journal of Biosciences and Medicines
84. Nonalcoholic fatty liver disease: What comes before and what are the consequences?
    Fernando Bril · 2024 · Elsevier eBooks
85. STEATOSIC LIVER DISEASE AND CARDIOVASCULAR DISEASES: ASSOCIATION, PROGNOSIS AND TREATMENT
    Т. В. Ткаченко, Halyna Tomashkevych · 2023 · Modern medicine pharmacy and psychological health
86. The Pan-PPAR Agonist Lanifibranor Reverses Metabolic Dysfunction in People with Type 2 Diabetes and MASLD: A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial
    Diana Barb, Srilaxmi Kalavalapalli, Eddison Godinez Leiva, Fernando Bril, Philippe Huot-Marchand, Lucile Lucile, Jens T. Rosenberg, Jean‐Louis Junien, Pierre Broqua, Andrea Ortiz Rocha et al. · 2024 · SSRN Electronic Journal
87. Pharmacologic treatment of NAFLD/NASH and their related comorbidities
    Sun H. Kim, Paul Yien Kwo · 2024 · Elsevier eBooks
88. Diabetes Mellitus and Non-alcoholic Fatty Liver Disease (NAFLD)
    Yusuf Karadeniz · 2023
89. Beyond Glucose: Empagliflozin’s Impact on Fatty Liver in Patients with Type 2 Diabetes; A True Game Changer
    Qamar Sajad, Khurshid Ahmad Khan, Aijaz Zeeshan Khan, Danish Khan, Javeid Iqbal, Muhammad Ibrar Mustafa · 2025 · Indus journal of bioscience research.
90. Evaluation of Clinical Efficacy of Smart Insulin for Diabetes Management: A Systematic Review
    Chintan Doshi · 2025 · Indian Journal of Medical Biochemistry
91. Pharmacologic intervention of nonalcoholic steatohepatitis and related cirrhosis
    Alam Zeb · 2025 · Elsevier eBooks
92. Additional file 1 of Association between serum insulin levels and heart failure-related parameters in patients with type 2 diabetes and heart failure treated with canagliflozin: a post-hoc analysis of the randomized CANDLE trial
    Tanaka, Atsushi, Imai, Takumi, Michio Shimabukuro, Taguchi, Isao, Akira Sezai, Toyoda, Shigeru, Watada, Hirotaka, Junya Ako, Node, Koichi · 2022 · Figshare
93. Sodium-glucose cotransporter 2 inhibitors facilitate cell phenotype conversion of alpha cells through progenitors to beta cells by activating Ppargc1α in diabetic mice
    Yafei Jiang, Dandan Wang, Ming Tao, Xiaona Cui, Jian Li, Tianjiao Wei, Jin Yang, Tianpei Hong, Rui Wei · 2026 · Chinese Medical Journal
94. Impact of empagliflozin on liver fat reduction in type 2 diabetes and NAFLD: A systematic review and meta-analysis
    Muhammad Umais, Hooriah Imtiaz, Muhammad Shaheer Luqman, Sidra Anwar, Muhammad Umer Iftikhar, Kanwal Maheshwari, Zarine Tasnim Sara, Noor ul Huda Naseem, Firose Afra Ibnath, Abdul Rehman Shah Syed et al. · 2026 · Endocrine
95. Corrigendum. Multidisciplinary clinical practice guideline on the management of metabolic hepatic steatosis
    Manuel Romero-Gómez, Javier Escalada, Mar Noguerol, Antonio Pérez, Juana Carretero, Javier Crespo, Juan J Mascort, Ignacio Aguilar, Francisco Tinahones, Pedro Cañones et al. · 2026 · Gastroenterología y Hepatología (English Edition)
96. Impact of modern glucose-lowering therapies on metabolic dysfunction-associated steatotic liver disease in type 2 diabetes
    A. M. Urbanovych, N.Ya. Sidelnyk, Orysia Lishchuk · 2026 · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
97. Novel Approaches to Diagnosing and Treating Non-alcoholic Fatty Liver Disease: Opportunities and Accomplishments
    Ildar Akhmetovich Uzyanbaev, Sofya Timoshenko, Л. В. Спирина, М.В. Матвеева · 2026 · Current Drug Targets
98. Metabolic Dysfunction–Associated Steatotic Liver Disease as a Systemic Driver of Heart Failure With Preserved Ejection Fraction: Mechanistic Insights and Emerging Therapeutic Perspectives
    Junli Wu, Wenwen Zheng, Qianxian Qi, Chao‐Jie He, Changlin Zhai, Hongyan Fan · 2026 · Reviews in Cardiovascular Medicine
99. Prise en charge des patients atteints de diabète de type 2 et de MASLD : synthèse et position commune selon l’AFEF et la SFD
    Yasmina Chouik, Clémence M. Canivet, Jean‐Baptiste Julla, Thomas Mouillot, Lucia Parlati, Alexia Rouland, Sarra Smati, Blandine Tramunt, Rodolphe Anty, Jérôme Boursier et al. · 2026 · Médecine des Maladies Métaboliques
100. Empagliflozin in the Absence of Diabetes: A Systematic Review of Its Anthropometric and Metabolic Effects in Humans and Animals
     Farima Farsi, Dorsa Ghorban Sarvi, Mohammadmahdi Abbasi, Shirin Hasani‐Ranjbar · 2026 · International Journal of Endocrinology